References
- Hamilton RJ. Metformin for castrate-resistant prostate cancer: learning more about an old dog’s new tricks. Eur Urol. 2014;66(3):475–477.
- Rothermundt C, Hayoz S, Templeton AJ, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014;66(3):468–474.
- Gillessen S, Gilson C, James N, et al. Repurposing metformin as therapy for prostate cancer within the STAMPEDE Trial Platform. Eur Urol. 2016;70(6):906–908.
- Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22:1102–1109.
- Haring A, Murtola TJ, Talala K, et al. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2017;51(1):5–12.
- Preston MA, Riis AH, Ehrenstein V, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66(6):1012–1020.
- Patasius A, Innos K, Barchuk A, et al. Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine. BMJ Open. 2019;9(10):e031856.
- Kincius M, Patasius A, Linkeviciute-Ulinskiene D, et al. Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients. Aging Male. 2020;1–6.